Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	3.1	1.07	0.29	0.42
Research & Development	0.94	0.14	0.07	0.18
Operating Expenses	4.04	1.21	0.36	0.6
Operating Income	-4.04	-1.21	-0.36	-0.6
Interest Expense	-2.4	-0.1	-	-
Pretax Income	-20.54	-1.31	-0.36	-0.6
Income Tax Expense	-	0	0	0
Net Income	-20.54	-1.31	-0.36	-0.6
Net Income to Common	-20.54	-1.31	-0.36	-0.6
Shares Outstanding (Basic)	50	440	443	-
Shares Outstanding (Diluted)	50	440	443	-
Shares Change (YoY)	-88.83%	-0.68%	-	-
EPS (Basic)	-0.41	-0.00	-0.00	-
EPS (Diluted)	-0.41	-0.00	-0.00	-
EBIT	-4.04	-1.21	-0.36	-0.6

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q